<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00315549</url>
  </required_header>
  <id_info>
    <org_study_id>EFC6134</org_study_id>
    <secondary_id>HMR3647B/3006</secondary_id>
    <nct_id>NCT00315549</nct_id>
  </id_info>
  <brief_title>TELI TAD - Telithromycin in Tonsillitis in Adolescents and Adults</brief_title>
  <official_title>Multinational, Randomized, Double Blind, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 800 mg od Versus 10 Days Penicillin V 500 mg Tid in Adolescent and Adult Subjects Equal to or Over 13 Years With Streptococcus Pyogenes Tonsillitis/Pharyngitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      This is a multinational, randomized (1:1), double blind, comparator-controlled, 2 parallel&#xD;
      treatment group study in subjects equal to or over 13 years of age, with Streptococcus&#xD;
      pyogenes tonsillitis/pharyngitis (T/P). Each subject will receive either telithromycin, 400&#xD;
      mg over-encapsulated tablets, 800 mg once daily for 5 days or penicillin V 250 mg&#xD;
      over-encapsulated tablets, 500 mg three times daily for 10days. Matching placebo capsules&#xD;
      will be dispensed to maintain the blind between the treatment groups.A positive rapid&#xD;
      identification test for streptococcal Group A antigen will be required for all subjects at&#xD;
      Visit 1 (Day 1) for entry into the study. Throat swab specimens for bacterial culture,&#xD;
      identification, and antibiotic-susceptibility testing will be taken at Visits 1, 3 and 4.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Pediatric development program terminated by sponsor&#xD;
  </why_stopped>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the bacteriologic efficacy of 5-days of telithromycin to 10-days of penicillin V insubjects at the posttherapy/test-of-cure (TOC) visit in the per protocol population.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the bacteriologic efficacy of 5-days of telithromycin to 10-days of penicillin V insubjects at the posttherapy/test-of-cure (TOC) visit andlate posttherapy visit (Visit 4) in the bacteriologic modified intent to treat population.</measure>
  </secondary_outcome>
  <enrollment type="Actual">233</enrollment>
  <condition>Tonsillitis</condition>
  <condition>Pharyngitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telithromycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Penicillin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age equal to or over 13 years;&#xD;
&#xD;
          -  For female subjects, the following conditions are to be met:&#xD;
&#xD;
          -  Subject is premenarchal or surgically incapable of bearing children,&#xD;
&#xD;
               -  Subject is of childbearing potential and all of the following conditions are met:&#xD;
&#xD;
               -  Have normal menstrual flow within 1 month before study entry,&#xD;
&#xD;
                    -  Have negative pregnancy test (urine pregnancy test sensitive to at least 50&#xD;
                       mU/mL, and&#xD;
&#xD;
                    -  Must agree to use an accepted method of contraception throughout the study&#xD;
                       (if sexually active);&#xD;
&#xD;
          -  Clinical diagnosis of acute tonsillitis/pharyngitis caused by Streptococcus pyogenes&#xD;
             based on:&#xD;
&#xD;
               -  A positive result from a rapid detection test for Group A streptococcal antigen&#xD;
                  and submission of a throat swab specimen for bacterial culture, identification,&#xD;
                  and antibiotic-susceptibility testing; and&#xD;
&#xD;
               -  A sore and scratchy throat and/or pain on swallowing (odynophagia) together with&#xD;
                  at least 2 of the following clinical signs:&#xD;
&#xD;
                    -  Tonsil and/or pharyngeal erythema and/or exudate;&#xD;
&#xD;
                    -  Cervical adenopathy;&#xD;
&#xD;
                    -  Uvular edema;&#xD;
&#xD;
                    -  Fever&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptoms that collectively suggest nonstreptococcal T/P (eg, laryngitis, coryza,&#xD;
             conjunctivitis, diarrhea, cough);&#xD;
&#xD;
          -  History of positive throat culture for Streptococcus pyogenes in the absence of&#xD;
             clinical signs and symptoms of T/P;&#xD;
&#xD;
          -  Infection of the deep tissues of the upper respiratory tract (eg, epiglottitis,&#xD;
             retropharyngeal or buccal cellulitis, or abscess of the retropharynx, tonsil, or&#xD;
             peritonsillar area) or of the suprapharyngeal respiratory tract and its connecting&#xD;
             structures (eg, sinusitis, otitis media, or orbital/periorbital cellulitis);&#xD;
&#xD;
          -  History of rheumatic heart disease;&#xD;
&#xD;
          -  Known congenital prolonged QT syndrome;&#xD;
&#xD;
          -  Known or suspected uncorrected hypokalemia (≤3 mmol/L [mEq/L) or hypomagnesemia or&#xD;
             bradycardia (&lt;50 bpm);&#xD;
&#xD;
          -  Known impaired renal function, as shown by creatinine clearance ≤25 mL/min&#xD;
&#xD;
          -  Myasthenia gravis;&#xD;
&#xD;
          -  History of hypersensitivity or intolerance to macrolides, penicillins, or&#xD;
             cephalosporins;&#xD;
&#xD;
          -  Previous enrollment in this study or previous treatment with telithromycin;&#xD;
&#xD;
          -  Children of the investigator or subinvestigator, research assistant, pharmacist, study&#xD;
             coordinator, other staff, or relative thereof directly involved in the conduct of the&#xD;
             protocol.&#xD;
&#xD;
          -  Is currently being treated with systemic antibacterials or has been treated with&#xD;
             systemic antibacterials within 14 days prior to enrollment;&#xD;
&#xD;
          -  Has been treated with any investigational medication within the last 30 days;&#xD;
&#xD;
          -  Has been treated with rifampicin, phenytoin, carbamazepine, or St. John's wort within&#xD;
             the last 2 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>San Isidro</city>
        <state>Buenos Aires</state>
        <zip>1642</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Providencia</city>
        <state>Santiago</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>San Jose</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Chile</country>
    <country>Costa Rica</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <study_first_submitted>April 14, 2006</study_first_submitted>
  <study_first_submitted_qc>April 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2006</study_first_posted>
  <last_update_submitted>April 2, 2009</last_update_submitted>
  <last_update_submitted_qc>April 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Tonsillitis</keyword>
  <keyword>pharyngitis</keyword>
  <keyword>penicillin</keyword>
  <keyword>telithromycin</keyword>
  <keyword>ketolides</keyword>
  <keyword>clinical trials</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharyngitis</mesh_term>
    <mesh_term>Tonsillitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Penicillins</mesh_term>
    <mesh_term>Telithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

